Recruiting Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study NCT07089199 Conditions Anlotinib, NSCLC, Nab-paclitaxel, +1 more Locations Qilu Hospital of Shandong University — Jinan, Shandong, China View Trial Details
Recruiting Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer NCT07233252 Conditions Kidney-sparing, Nab-paclitaxel, PD-1 Inhibitor, +2 more Locations The Second Hospital of Tianjin Medical University — Tianjin, Outside U.S., China View Trial Details
Recruiting Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer NCT04159142 Conditions Breast Diseases, Breast Neoplasms, Nab-paclitaxel, +6 more Locations The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China View Trial Details
Recruiting Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer NCT04138719 Conditions Breast Cancer, Breast Diseases, Breast Neoplasms, +7 more Locations The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China View Trial Details
Recruiting Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC NCT07126119 Conditions Nab-paclitaxel, Neoadjuvant Therapy, PD-1 Inhibitor, +1 more Locations The Second Hospital of Tianjin Medical University — Tianjin, Outside U.S., China View Trial Details
Recruiting Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer NCT07125547 Conditions Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Kidney-sparing, +14 more Locations The Second Hospital of Tianjin Medical University — Tianjin, Outside U.S., China View Trial Details
